Wedmont Private Capital Purchases 20,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE)

Wedmont Private Capital grew its position in Cue Biopharma, Inc. (NASDAQ:CUE) by 100.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Wedmont Private Capital owned 0.08% of Cue Biopharma worth $76,000 at the end of the most recent reporting period.

Separately, Navalign LLC bought a new position in shares of Cue Biopharma in the fourth quarter worth about $66,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock opened at $1.35 on Monday. The firm has a fifty day moving average of $1.63 and a two-hundred day moving average of $2.13. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.47 and a current ratio of 2.47. The stock has a market capitalization of $65.66 million, a price-to-earnings ratio of -1.27 and a beta of 1.99. Cue Biopharma, Inc. has a 52 week low of $1.26 and a 52 week high of $4.89.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Thursday, May 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.05. The firm had revenue of $1.72 million for the quarter, compared to analyst estimates of $0.73 million. Cue Biopharma had a negative return on equity of 128.30% and a negative net margin of 711.84%. As a group, equities research analysts predict that Cue Biopharma, Inc. will post -0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

CUE has been the subject of a number of research reports. Oppenheimer reissued an “outperform” rating and issued a $10.00 price target on shares of Cue Biopharma in a report on Tuesday, April 9th. Piper Sandler restated an “overweight” rating and set a $8.00 target price on shares of Cue Biopharma in a research report on Wednesday, April 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $8.00 price target on shares of Cue Biopharma in a report on Tuesday, April 9th. Finally, Jefferies Financial Group began coverage on Cue Biopharma in a report on Wednesday, March 13th. They set a “buy” rating and a $6.00 price objective for the company.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.